|
|
News Breaks | | | | January 6, 2013 | | 18:25 EDT |  | ALNY | Alnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1
Alnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1 for the treatment of acute intermittent porphyria, an ultra-rare genetic disease caused by loss of function mutations in an enzyme in the heme biosynthesis pathway that result in acute and/or recurrent life-threatening attacks with severe abdominal pain, peripheral and autonomic neuropathy, and neuropsychiatric manifestations. In aggregate, we believe that execution on our ‘Alnylam 5x15’ programs and our ambitious goals for 2013 and beyond will enable continued advancement of RNAi therapeutics as innovative medicines for patients, resulting in value creation for our shareholders.” | |
|
News For ALNY From The Last 14 Days Check below for free stories on ALNY the last two weeks. |
|
|
| May 17, 2013 | | 08:04 EDT | | ALNY | Alnylam announces proof-of-concept data from RNAi program
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT |  | ALNY | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 14, 2013 | | 08:43 EDT |  | ALNY | Alnylam has multiple upcoming positive catalysts, says JMP Securities
JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. | |
|
|
|
|
|
|
